Inventiva Aktie
| 4,59EUR | 0,07EUR | 1,44% |
WKN DE: A2DLV9 / ISIN: FR0013233012
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 105 | 113 | 123 | 119 | 77 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,04 | 0,11 | 0,14 | 0,08 | 0,06 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 115 | 106 | 48 | 111 | 244 |
| Summe Anlagevermögen | 6 | 10 | 21 | 7 | 5 |
| Summe Aktiva | 121 | 116 | 69 | 119 | 249 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 33 | 71 | 102 | 226 | 278 |
| Summe Eigenkapital | 88 | 45 | -32 | -107 | -29 |
| Summe Passiva | 121 | 116 | 69 | 119 | 249 |
Adresse
| 50, rue de Dijon, 21121 Daix | |
| Telefon | +33 (3) 80-44-75-00 |
| Internet | http://www.inventivapharma.com |
Management
|
Andrew Obenshain
Chief Executive Officer & Director |
|
Annick Schwebig
Independent Director |
|
Axel-Sven Malkomes
Chief Financial Officer |
|
Eric Marie Albert Duranson
General Counsel |
|
G. Andre Turenne
Independent Director |
|
Heinz Christoph Mäusli
Independent Director |
|
Jason A. Campagna
Chief Medical Officer & President-Research |
|
Jean Volatier
EVP-Finance & Corporate Social Responsibility |
|
Mark E. Pruzanski
Chairman |
|
Martine Zimmermann
EVP-Regulatory Affairs & Quality Assurance |
|
Nazira Arma
Chief Commercial Strategy Officer |
|
Pamela Herbster
Chief People Officer |
|
Pascaline Clerc
Executive VP-Strategy & Corporate Affairs |
|
Renée Julie Elisabet Aguiar-Lucander
Director |
|
Srinivas Akkaraju
Independent Director |
|
Susan Coles
Chief Legal Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.